First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

• Status: Completed
• Trial end date: 2015-08-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bevacizumab; Cediranib; Fluorouracil; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• Clinical Diagnosis of colon or rectal cancer

• No prior systemic therapy for metastatic disease. Any adjuvant/neoadjuvant oxaliplatin therapy must have been received >12 months prior to study entry and adjuvant/neoadjuvant 5-FU must have been received >6 months prior to study entry.

Exclusion Criteria:

• Prior treatment with a VEGF Inhibitor, including bevacizumab and cediranib.

• Poorly controlled hypertension